Pharvaris (PHVS) Prepaid Assets (2019 - 2026)
Pharvaris' (PHVS) quarterly Prepaid Assets came in at $6.7 million in Q1 2026, down 9.12% YoY from $7.4 million in Q1 2025, and up 96.82% on a QoQ basis from $3.4 million in Q4 2025.
Analysis
Pharvaris (PHVS) Prepaid Assets (2019 - 2026) Analysis & Trends
Pharvaris (PHVS) has 8 years of Prepaid Assets data on file, last reported at $6.7 million in Q1 2026.
- Quarterly Prepaid Assets fell 9.12% year-over-year to $6.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.7 million (down 9.12% YoY) and the FY2025 annual result came in at $3.3 million, down 46.63% from the prior year.
- Prepaid Assets advanced to $6.7 million in Q1 2026, from $3.4 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $12.4 million in Q1 2023 to a low of $3.4 million in Q4 2025.
- A 5-year average of $6.8 million and a median of $6.1 million in 2024 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2022 — Prepaid Assets jumped 172.65% — and 2024, when it tumbled 55.42%.
- Tracing PHVS's Prepaid Assets over 5 years: stood at $4.7 million in 2022, then grew by 27.2% to $6.0 million in 2023, then grew by 2.28% to $6.1 million in 2024, then slumped by 44.31% to $3.4 million in 2025, then surged by 96.82% to $6.7 million in 2026.
- The last three Prepaid Assets figures came in at $6.7 million (Q1 2026), $3.4 million (Q4 2025), and $5.8 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Pharvaris | 2.10 Bn | 1.73 Bn | 85,072.10 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3,865.75 Bn |
| Mar 31, 2026 | 6,731.62 Bn |
| Dec 31, 2025 | 3,420.21 Bn |
| Sep 30, 2025 | 5.80 Mn |
| Jun 30, 2025 | 6.80 Mn |
| Mar 31, 2025 | 7.41 Mn |
| Dec 31, 2024 | 6,141.24 Bn |
| Sep 30, 2024 | 4.78 Mn |
| Jun 30, 2024 | 6.38 Mn |
| Mar 31, 2024 | 8.25 Mn |
| Dec 31, 2023 | 6,004.50 Bn |
| Sep 30, 2023 | 10.72 Mn |
| Jun 30, 2023 | 10,325.70 Bn |
| Mar 31, 2023 | 12.40 Mn |
| Dec 31, 2022 | 4,720.53 Bn |
| Sep 30, 2022 | 4.27 Mn |
| Jun 30, 2022 | 4.88 Mn |
| Mar 31, 2022 | 5.84 Mn |
| Dec 31, 2021 | 1,731.35 Bn |
| Sep 30, 2021 | 3.99 Mn |